Therapeutic insights into the treatment of Sickle cell disease and β-thalassemias: Argonaute-2 decreases sickling of erythrocytes via up regulation of fetal HbF, 25/September/2014, 08.23 am

Therapeutic insights into he treatment of stroke, multiple sclerosis, and Alzheimer’s disease: C/EBPβ promotes neuroprotection via up regulation of its target gene, 26/September/2014, 08.18 am
September 26, 2014
Therapeutic insights into Protecing Genome integrity: Stem cell protein Oct-4 increases the expression of an oncogenic protein Aurora B via up regulation of its target gene, 26/September/2014, 08.38 am
September 26, 2014
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, Therapeutic insights into the treatment of Sickle cell disease and β-thalassemias: Argonaute-2 decreases sickling of erythrocytes via up regulation of fetal HbF, 25/September/2014, 08.23 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Significance: This study suggests that Argonaute-2by regulating the expression of its target gene, it  may increase the levels of HbF.  Thus, pharmacological formulations encompassing Argonaute-2 activator” may be used to treat: (1) Sickle cell disease ;  (2) β-thalassemias; and (3) disease conditions that has lower levels of HbF

* Research cooperation

Comments are closed.